Badges [ 6 ] [-]
Memberships [ 1 ] [+]
Activity Stream [+]
Ideas Contributed [ 3 ] [+]
What is the possibility of investing funds primarily in clinically-relevant models where the findings could be translated in to human diseases?
Although the NCRR and NIGMS used to have a mechanism to train new generation of clinical & translational scientists, this program was stopped. Why?
What is the possibility of other institutes to come up with the priority of funding resources in this regard?
Currently, there are limited, if none, funding resources to synthesize and screen potentially therapeutic molecules, based on supportive findings in cells, biopsy tissues from the patients with the disease in question, and the preliminary data to support the development of a series of compounds to screen them for their pharmacokinetics, pharmacodynamics, toxicity and use in clinically-relevant large animal models.